Loading data for ACXP — first visit, this takes a few seconds.

Acurx Pharmaceuticals, Inc. (ACXP)

NasdaqCM: ACXP · 即時價格 · USD

1.41

-0.02 (-1.40%)

收盤價： Sep 11, 2026, 3:59 PM

1.39

-0.43%

盤後: 6:30 PM

提醒

Alert

股價、關鍵數字和最新消息，都在這一頁。

-1.40% (1D)

買價	1.01
市值	6.02M
營收 (ttm)	n/a
淨利（ttm）	-7.51M
	-2.02
	-2.44
	n/a
	-0.8
P/B (ttm)	0.80
P/S (ttm)	0.00
財報日期	Nov 11, 2026

賣價	1.81
成交量	32,361
20 日平均成交量	123,829
開盤價	1.41
前收盤價	1.43
當日區間	1.41 - 1.43
52 週範圍	1.31 - 8.34
分析師	n/a
目標價	n/a
股利	n/a
除息日	n/a

關於 ACXP

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-pos...

[閱讀更多]

產業 Biotechnology

類股 Healthcare

IPO 日期 Jun 25, 2021

員工 4

證券交易所 NasdaqCM

股票代號 ACXP

網站 https://www.acurxpharma.com

完整的公司簡介

財務表現

Acurx Pharmaceuticals 在 2025 年的營收為 0，較前一年的 0 增加 undefined%。淨利為 -7.97M，較前期減少 -43.51%。

財務報表

財報驚奇

Acurx Pharmaceuticals 已於 Aug 13, 2026 公布季度財報：

營收為 $0 低於預期 $0, 年增 NaN% 成長.
每股盈餘為 -0.53 低於預期 -0.10, 年增 71.96% 成長.

下次財報發布

Acurx Pharmaceuticals, Inc. 的下次財報預計於 Nov 11, 2026, 開盤前。
分析師預估營收 ... 升級

價格為何變動

新聞動態

3 週前 · GuruFocus.com

Acurx Pharmaceuticals Inc (ACXP) (Q2 2026) Earnings Call Highlights: FDA Signals Potential ...

Company advances toward pivotal Phase 3 trial with conditional FDA guidance, while securing funding to support operations for at least one year.

4 週前 · Moby

Acurx Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary

Moby summary of Acurx Pharmaceuticals, Inc.'s Q2 2026 earnings call

3 月前 · Zacks

Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's Why

Acurx Pharmaceuticals (ACXP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).